Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 45
- Registration Number
- NCT02195869
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 16
- Registration Number
- NCT02169180
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT02165397
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02160015
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02159755
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 35
- Registration Number
- NCT02142049
- Locations
- 🇺🇸
SITE-1, Duarte, California, United States
🇺🇸SITE-10, Orange, California, United States
🇺🇸SITE-6, Bethesda, Maryland, United States
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT02129062
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
- Conditions
- Adult B Acute Lymphoblastic LeukemiaIntraocular LymphomaNodal Marginal Zone LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 2 Follicular LymphomaWaldenstrom MacroglobulinemiaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT02109224
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
🇺🇸Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 138
- Registration Number
- NCT02077166
- Locations
- 🇺🇸
Baylor Charles Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 529
- Registration Number
- NCT02048813
- Locations
- 🇺🇸
Alaska Regional Hospital, Anchorage, Alaska, United States
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.